109% longer lifespan in mice, and the FDA just approved the human trial

Mice injected with a three-gene cocktail at the human equivalent of age 77 lived 109% longer than untreated controls. Not 10%. Not 20%. Their remaining lifespan more than doubled, and their hearts and livers showed measurable age reversal on DNA methylation clocks.

That study, published in Cellular Reprogramming by a team at Rejuvenate Bio, is the preclinical foundation behind the most significant regulatory milestone in longevity science to date: on January 28, 2026, the FDA cleared Life Biosciences' IND application for ER-100, the first partial epigenetic reprogramming therapy ever authorized for human testing.

What ER-100 actually does to your cells

The therapy delivers three of the four Yamanaka factors (OCT4, SOX2, and KLF4, collectively called OSK) via an adeno-associated virus vector. These are the same Nobel Prize-winning proteins that can fully reset a cell back to a stem-cell state. The breakthrough was figuring out how to use only three of them, for controlled durations, so cells rejuvenate without losing their identity. Your retinal cell stays a retinal cell. It just functions like a younger one.

In the mouse study, researchers used a cycling protocol: one week of gene expression on, one week off, delivered systemically to 124-week-old mice (roughly equivalent to 77-year-old humans). The treated group's median remaining lifespan jumped from 8.86 weeks to 18.5 weeks. Their frailty scores dropped significantly. DNA methylation clocks in liver tissue reversed with statistical significance (p=0.0139), and heart tissue followed (p=0.0414).

The human trial nobody in the supplement aisle can match

The Phase 1 trial (NCT07290244) will enroll patients with two conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). Both involve retinal ganglion cell damage from aging. NAION, the most common acute optic neuropathy in adults over 50, currently has zero approved treatments.

ER-100 is injected directly into the eye, where it reprograms the epigenome of damaged retinal cells. Non-human primate studies already showed restored DNA methylation patterns enriched for neuronal regeneration, with measurable improvements on electroretinograms.

Results are expected by late 2026 or early 2027. The trial tests safety first, but the preclinical signal is unusually strong for a first-in-human study.

Why the billion-dollar supplement industry should pay attention

The global anti-aging supplement market was valued at $4.88 billion in 2025. NMN, resveratrol, NAD+ precursors: all of them reliably boost certain blood markers. None of them have cleared the regulatory bar ER-100 just passed.

NMN supplements, for example, consistently raise blood NAD+ levels in clinical trials. But when researchers look at clinically relevant outcomes (cognitive function, muscle performance, actual biological age markers) the results are modest at best. A meta-analysis of NMN human trials found improvements in triglyceride levels for overweight participants but no significant effect on most body composition or aging-related endpoints.

The gap is not about whether supplements work in some narrow biochemical sense. They do. The gap is between raising a biomarker and actually reversing cellular aging, which is what the mouse data behind ER-100 demonstrated at the epigenetic level.

What this means if you care about living longer

David Sinclair, the Harvard geneticist who co-founded Life Biosciences and proposed the Information Theory of Aging (the idea that aging is primarily a loss of epigenetic information, not genetic mutation), is watching his hypothesis face its first real clinical test. If ER-100 shows even a fraction of the preclinical effect in humans, it validates a fundamentally different approach to aging: not slowing decline, but partially reversing it.

The competitive landscape reflects how seriously the field takes this. Altos Labs launched with $3 billion in backing from investors including Jeff Bezos. NewLimit raised $130 million. Life Biosciences, with fewer than 20 employees, reached the clinic first.

For now, this is a safety trial for eye disease, not an anti-aging pill. But the underlying mechanism, partial epigenetic reprogramming, is platform technology. If it works in the eye, the same approach could target the liver, heart, brain, or any tissue where aging degrades function.

The first person to receive a cellular rejuvenation therapy will likely do so within months. Whether you spend $50 a month on longevity supplements or nothing at all, that single data point will tell us more about human aging than the entire supplement industry has produced in decades.